We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Circulogene Theranostics, UAB Comprehensive Cancer Center Announce Research Agreement
News

Circulogene Theranostics, UAB Comprehensive Cancer Center Announce Research Agreement

Circulogene Theranostics, UAB Comprehensive Cancer Center Announce Research Agreement
News

Circulogene Theranostics, UAB Comprehensive Cancer Center Announce Research Agreement

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Circulogene Theranostics, UAB Comprehensive Cancer Center Announce Research Agreement"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Circulogene Theranostics has announced a research agreement with the University of Alabama Birmingham (UAB) Comprehensive Cancer Center. The first clinical trial to be conducted in coordination with the UAB Comprehensive Cancer Center – one of the nation’s leading cancer research and treatment centers – will study the effectiveness of traditional tissue biopsies compared to liquid biopsies in tumor detection and monitoring.

“We’re eager to work with such a highly respected group of researchers who recognize the unique ability of our proprietary enrichment technique to provide maximal DNA data output with minimal input,” said Circulogene Theranostics CEO Mike Mullen. “We look forward to aligning with the world-renowned UAB cancer center to further evaluate the effectiveness of our droplet-volumes-of-blood technology.”

Commercially launched in November 2015, Circulogene’s cfDNA liquid biopsy products enable the fast, accurate and personalized testing of 10 tumor types, including breast, lung and colon cancer. Non-invasive liquid biopsy techniques represent a potential major advance over traditional surgical tumor biopsies, which are costly, time consuming and only sample a small portion of tumor tissue. This can result in the missing of critical tumor information, which can significantly change a patient’s treatment and prognosis.

Circulogene’s proprietary enrichment methodology, which can collect more than 100 times more cfDNA with just 1/10 of the blood compared to the current industry standard for non-invasive liquid biopsy testing, is a powerful research target.

The company’s droplet-volumes-of blood methodology is capable of detecting nearly 3000 cancer mutations on 50 well-established cancer-associated genes for its 10 cancer profiles and potentially provides the most precise, rapid and cost-effective monitoring and targeted treatment of cancer possible.

Circulogene is Clinical Laboratory Improvement Amendments (CLIA) certified and currently provides testing for the following cancers: breast, colorectal, lung, gastric, gastrointestinal stromal (GIST), hematological, melanoma, ovarian, pancreatic and thyroid.

Advertisement